Methods of treating injuries or conditions related to CNS edema
AssigneeRemedy Pharmaceuticals, Inc.
InventorSven Martin Jacobson
Life of this patent
Estimating the term…
Abstract
The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.
Claims20
A method of reducing late neurological deterioration or death in a subject following a large hemispheric infarction, wherein the subject has a brain lesion volume of greater than 100 cc, comprising administering a glyburide to the subject, wherein the administering includes a first continuous infusion and a second continuous infusion of glyburide lasting cumulatively for at least 72 hours after starting the first continuous infusion, wherein the first continuous infusion is started within 9 hours following the subject experiencing the large hemispheric infarction.
A method of reducing cerebral midline shift in a subject following a large hemispheric infarction, wherein the subject has a brain lesion volume of greater than 100 cc, comprising:
- administering to the subject glyburide following the subject experiencing the large hemispheric infarction, wherein the administering includes a first continuous infusion and a second continuous infusion of glyburide lasting cumulatively for at least 72 hours after starting the first continuous infusion, wherein the first continuous infusion is started within 9 hours following the subject experiencing the large hemispheric infarction, wherein the method reduces the cerebral midline shift as determined over a population based on the degree of cerebral midline shift in patients treated with the continuous infusions compared to a similar population that was not treated with the continuous infusions.
Dependencies are inferred from the claim text.